Sorafenib should not be used in the adjuvant setting in patients with resected renal cell carcinoma at intermediate or high risk of relapse, says the SORCE research team.
Findings from the JAVELIN Renal 101 trial of patients with advanced renal cell carcinoma suggest front-line use of avelumab plus axitinib is superior to sunitinib for patients with sarcomatoid histology and for those who did not undergo upfront cytoreductive nephrectomy.
Survivors of the 20 most common site-specific cancers, including lung and prostate, are at increased risk for cardiovascular disease in the years that follow diagnosis and treatment, show data published in The Lancet.
Patients with previously untreated advanced renal cell carcinoma derive greater long-term survival benefits from nivolumab plus ipilimumab than from sunitinib, according to the latest results from the phase III CheckMate 214 trial.
Five-year data from the phase I CA209-003 trial indicate that the PD-1 inhibitor nivolumab is associated with long-term survival benefits among heavily pretreated patients with advanced renal cell carcinoma or non-small-cell lung cancer.